Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous vitamin C versus placebo in septic ARDS
2020-003923-40Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and acute respiratory distress syndrome (ARDS) comparing High-dose intravenous vitamin C with Placebo (2 arms). Primary endpoint: Death or persistent organ dysfunction at 28 days. Started Nov 2020; status: active.
02
Drugs
ascorbic acid
03
Conditions
sepsisacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-003923-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003923-40.